ganaplacide

10/05/2021 - "Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study."
10/05/2021 - "In contrast, 50 mg KAF156 protected 3 of 14 participants from infection, and doses of 800, 300, and 100 mg KAF156 protected all subjects against infection. "
10/05/2021 - "In part 2, all participants treated with placebo or 20 mg KAF156 developed malaria infection. "
10/05/2021 - "In part 1, all participants treated with KAF156 and none of those randomized to placebo were protected against malaria infection. "
10/05/2021 - "Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model. "

11/01/2014 - "This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers determined the maximum oral dose of KAF156 tolerated by healthy adults and derived pharmacokinetic data (including preliminary food effect) to enable dose calculations for malaria patients. "
09/01/2014 - "Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat, prevent, and block the transmission of malaria. "
10/01/2018 - "In the search for a 'magic bullet' in malaria therapy and prophylaxis facilitating single encounter radical cure and prophylaxis, ganaplacide demonstrates some promising properties toward this ultimate goal. "
10/05/2021 - "An exposure-response analysis suggested that a 24-hour postdose concentration of KAF156 of 21.5 ng/mL (90% confidence interval, 17.66-25.32 ng/mL) would ensure a 95% chance of protection from malaria parasite infection. "
10/05/2021 - "In part 2, all participants treated with placebo or 20 mg KAF156 developed malaria infection. "

01/01/2023 - "Ganaplacide plus lumefantrine-SDF was effective and well tolerated in patients, especially adults and adolescents, with uncomplicated P falciparum malaria. "
01/01/2023 - "We aimed to identify effective and well tolerated doses of ganaplacide plus lumefantrine solid dispersion formulation (SDF) in patients with uncomplicated Plasmodium falciparum malaria. "
01/01/2023 - "Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial."

01/01/2016 - "Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria."

10/05/2021 - "An exposure-response analysis suggested that a 24-hour postdose concentration of KAF156 of 21.5 ng/mL (90% confidence interval, 17.66-25.32 ng/mL) would ensure a 95% chance of protection from malaria parasite infection. "